title: Intravitreal injection of bevacizumab: changes in intraocular pressure related to ocular axial length.
abstract: OBJECTIVE
  To evaluate the immediate and short-term effects of intravitreal injection of 1.25 mg/0.05 ml of bevacizumab on intraocular pressure related to different ocular axial lengths.
  
  
  METHODS
  A prospective case series of consecutive patients referred to the Department of Ophthalmology, San Pietro-Fatebenefratelli Hospital, from September 2011 through January 2011.
  
  
  METHODS
  Twenty-five patients (10 men and 15 women, mean age 70.2 ± 8.98 years) scheduled for intravitreal injection of bevacizumab for the treatment of neovascular age-related macular degeneration were enrolled in this study. Axial length was measured preoperatively using IOLMaster. Intraocular pressure was measured before injection, after 1 min and after 15 min using Tono-Pen XL tonometry.
  
  
  RESULTS
  The mean intraocular pressure change following the intravitreal bevacizumab injection was 21.92 ± 6.95 mmHg after 1 min and 6.24 ± 3.77 mmHg after 15 min. The mean axial length of the examined eyes was 23.2 ± 1.06 mm. A good correlation was observed between the axial length and intraocular pressure rise after both 1 (R (2) = 0.752, p < 0.001) and 15 min (R (2) = 0.559, p < 0.001).
  
  
  CONCLUSIONS
  Patients undergoing intravitreal injection of 0.05 ml of bevacizumab can be exposed to intraocular pressure increases correlated to ocular axial length.
authors.affiliation: Fondazione G.B. Bietti-IRCCS, Via Livenza 3/5, 00198 Rome, Italy.
authors.forename: Andrea
authors.initials: A
authors.lastname: Cacciamani
authors.forename: Francesco
authors.initials: F
authors.lastname: Oddone
authors.forename: Mariacristina
authors.initials: M
authors.lastname: Parravano
authors.forename: Fabio
authors.initials: F
authors.lastname: Scarinci
authors.forename: Marta
authors.initials: M
authors.lastname: Di Nicola
authors.forename: Giorgio
authors.initials: G
authors.lastname: Lofoco
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D058452:Axial Length, Eye / Q000187:drug effects* / Q000503:physiopathology; D000068258:Bevacizumab; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D058449:Intravitreal Injections; D008268:Macular Degeneration / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab